Defilade Capital Management, L.P. — 13F Holdings & Portfolio
CIK 2088557 · latest 13F-HR filed 2026-06-12
Defilade Capital Management, L.P. manages $712.2M in 13F-reported U.S. long-equity assets across 31 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ZBH (7.35%), HSIC (6.46%), BDX (6.16%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions, exited 0, added to 1, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 625
EMERYVILLE, CA 94608
$712.2M
Long-equity book
31
Distinct positions
2026-03-31
Filed 2026-06-12
+0 / −0 / ↑1 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ZIMMER BIOMET HOLDINGS INC | ZBH | 98956P102 | $52.4M | 7.35% | 579,161 | SH |
| 2 | SCHEIN HENRY INC | HSIC | 806407102 | $46.0M | 6.46% | 624,037 | SH |
| 3 | BECTON DICKINSON & CO | BDX | 075887109 | $43.9M | 6.16% | 279,210 | SH |
| 4 | PFIZER INC | PFE | 717081103 | $41.1M | 5.77% | 1,464,129 | SH |
| 5 | DEXCOM INC | DXCM | 252131107 | $33.8M | 4.75% | 538,762 | SH |
| 6 | ICU MED INC | ICUI | 44930G107 | $32.8M | 4.61% | 254,291 | SH |
| 7 | INSMED INC | INSM | 457669307 | $31.9M | 4.48% | 194,909 | SH |
| 8 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $31.2M | 4.38% | 67,681 | SH |
| 9 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $30.7M | 4.31% | 315,972 | SH |
| 10 | GLOBUS MED INC | GMED | 379577208 | $30.5M | 4.29% | 354,350 | SH |
| 11 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $27.7M | 3.88% | 209,932 | SH |
| 12 | DENALI THERAPEUTICS INC | DNLI | 24823R105 | $26.1M | 3.67% | 1,359,969 | SH |
| 13 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $25.6M | 3.60% | 376,165 | SH |
| 14 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $22.4M | 3.15% | 1,504,536 | SH |
| 15 | ELANCO ANIMAL HEALTH INC | ELAN | 28414H103 | $22.3M | 3.13% | 931,121 | SH |
| 16 | PACS GROUP INC | PACS | 69380Q107 | $19.4M | 2.72% | 604,180 | SH |
| 17 | ELI LILLY & CO | LLY | 532457108 | $19.0M | 2.67% | 20,696 | SH |
| 18 | LANTHEUS HLDGS INC | LNTH | 516544103 | $18.9M | 2.66% | 249,401 | SH |
| 19 | INTEGER HLDGS CORP | ITGR | 45826H109 | $18.7M | 2.63% | 213,027 | SH |
| 20 | BIOGEN INC | BIIB | 09062X103 | $17.7M | 2.48% | 96,289 | SH |
| 21 | EVOMMUNE INC | EVMN | 30054Y107 | $15.6M | 2.19% | 678,589 | SH |
| 22 | TANDEM DIABETES CARE INC | TNDM | 875372203 | $14.6M | 2.05% | 761,905 | SH |
| 23 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $13.6M | 1.91% | 352,590 | SH |
| 24 | NUVALENT INC | NUVL | 670703107 | $13.3M | 1.87% | 129,950 | SH |
| 25 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $12.6M | 1.77% | 1,487,645 | SH |
| 26 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $11.9M | 1.67% | 51,895 | SH |
| 27 | ALIGN TECHNOLOGY INC | ALGN | 016255101 | $11.5M | 1.62% | 67,332 | SH |
| 28 | ELEDON PHARMACEUTICALS INC | ELDN | 28617K101 | $11.0M | 1.54% | 3,564,127 | SH |
| 29 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $10.7M | 1.50% | 842,928 | SH |
| 30 | BIOHAVEN LTD | BHVN | G1110E107 | $2.7M | 0.38% | 315,944 | SH |
| 31 | MEREO BIOPHARMA GROUP PLC | MREO | 589492107 | $2.5M | 0.35% | 7,558,756 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $712.2M | 31 | 0002088557-26-000005 |
| 2026-03-31 | 2026-06-12 | $712.2M | 31 | 0002088557-26-000006 |
| 2025-12-31 | 2026-02-13 | $737.7M | 33 | 0002088557-26-000002 |